FIELD: medicine.
SUBSTANCE: for simulation of non-alcoholic steatohepatitis in rats 4.25 g of melted beef fat and 0.43 g of powdered cholesterol per 100 g of body weight were administered to animals daily during 6 months with food. The method provides an adequate reproduction of the model.
EFFECT: proposed model is simple in execution, shows good reproducibility, lack of death in experimental animals and complexity in forming dismetabolic violations in liver and body as a whole typical for this disease.
4 tbl, 1 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF SIMULATING NON-ALCOHOLIC STEATOHEPATITIS IN RATS | 2015 |
|
RU2598351C1 |
| METHOD OF SIMULATING MULTIPLE ORGAN PATHOLOGY IN RATS | 2011 |
|
RU2453002C1 |
| METHOD OF SIMULATING NON-ALCOHOLIC FATTY LIVER DISEASE IN RATS | 2015 |
|
RU2600476C1 |
| METHOD FOR MODELING FATTY LIVER DISEASE OF MIXED GENESIS IN RATS | 2020 |
|
RU2757199C1 |
| METHOD FOR STEP-BY-STEP MODELING OF NONALCOHOLIC FATTY PANCREATIC DISEASE IN RATS | 2021 |
|
RU2770555C1 |
| ANTYSTEATOSIS AGENT | 2019 |
|
RU2702003C1 |
| METHOD FOR MODELLING NON-ALCOHOLIC FATTY LIVER DISEASE BY DIET RICH IN FRUCTOSE | 2019 |
|
RU2728418C1 |
| NALMEFEN, NALTREXONE OR DERIVATIVES THEREOF FOR USE IN TREATING (NON)-ALCOHOLIC STEATOHEPATITIS OR NON-ALCOHOLIC FATTY LIVER DISEASE | 2017 |
|
RU2717677C1 |
| USING LACTITOL AND AN ORAL DOSAGE FORM FOR TREATING AND PREVENTING NON-ALCOHOLIC FATTY LIVER DISEASE | 2018 |
|
RU2692243C1 |
| METHOD OF TREATING PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS ON BACKGROUND OF METABOLIC SYNDROME | 2015 |
|
RU2595815C1 |
